Octacarbonyldicobalt

Repeated dose toxicity: oral

Administrative data

Endpoint:

short-term repeated dose toxicity: oral

Type of information:

experimental study

Adequacy of study:

weight of evidence

Reliability:

2 (reliable with restrictions)

Rationale for reliability incl. deficiencies:

other: peer-reviewed database

Data source

Reference

Reference Type:

secondary source

Title:

Dicobalt octacarbonyl

Author:

GESTIS

Year:

2017

Bibliographic source:

http://gestis-en.itrust.de/nxt/gateway.dll?f=templates$fn=default.htm$vid=gestiseng:sdbeng

Materials and methods

Test guideline

Qualifier:

no guideline available

Principles of method if other than guideline:

not specified in database

GLP compliance:

not specified

Test material

Test material information

Constituent 1

Reference substance name:

Octacarbonyldicobalt

EC Number:

233-514-0

EC Name:

Octacarbonyldicobalt

Cas Number:

10210-68-1

Molecular formula:

C8O8Co2

IUPAC Name:

1,1,1,3,3,3-hexakis(oxidaniumylidynemethyl)-2,4-dioxo-1,3-dicobaltabicyclo[1.1.0]butane-1,1,3,3-tetrakis(ylium)

Test animals

Species:

other: rats and mice

Results and discussion

Effect levels

Key result

Dose descriptor:

other: TDLo

Remarks:

lowest published toxic dose

Effect level:

3 468 other: mg/kg bw

Remarks on result:

other: Initial toxic effects occurred following a total dose of 3468 mg/kg bw. Damage to the heart muscle, metabolic disturbances (hyperglycemia) and changes to the blood composition (changes to the erythrocyte count) were observed.

Target system / organ toxicity

Key result

Critical effects observed:

yes

Lowest effective dose / conc.:

3 468 other: mg/kg bw

System:

other: cardiac, endocrine, blood

Organ:

other: Damage to the heart muscle, metabolic disturbances (hyperglycemia) and changes to the blood composition (changes to the erythrocyte count) were observed.

Treatment related:

not specified

Dose response relationship:

not specified

Applicant's summary and conclusion

Conclusions:

Initial toxic effects occurred following a total dose of 3468 mg/kg bw. Damage to the heart muscle, metabolic disturbances (hyperglycemia) and changes to the blood composition (changes to the erythrocyte count) were observed.

Executive summary:

There is no available information on the methods used to determine the value for this endpoint. However, this information is taken from GESTIS database which is considered to be a reliable peer reviewed database. There it is reported that no experience reports on the consequences of repeated exposure to D. are available from occupational handling.

Even from animal experiments there are no data concerning occupationally relevant exposure pathways.

Based on the acute symptoms observed on persons exposed and in animal experiments, inflammatory changes are also to be expected following long-term exposure to D.

By comparison, it is not possible to estimate whether or not Co-conditioned damage to the lung parenchyma (lung fibrosis), particularly observed following exposure to Co dust (principally as hard metal dust), can also occur following exposure to Co carbonyles.

The only indications of systemic cumulative effects to date are derived from a subacute experiment on rats and mice: The animals received D. in oral doses corresponding to 5 - 20 % of the LD50 for 23 days. Initial toxic effects occurred following a total dose of 3468 mg/kg bw. Damage to the heart muscle, metabolic disturbances (hyperglycemia) and changes to the blood composition (changes to the erythrocyte count) were observed.

Although further examination is needed, for the present the findings indicate that in principle D. can produce similar effects as other inorganic Co compounds.

For these compounds, damage to the heart muscle, increased erythropoiesis or polycythemia as well as hypofunction of the thyroid gland were the most significant systemic effects found following prolonged (mostly oral) intake of high doses.